Local effect of adenosine 5′-triphosphate on indomethacin-induced permeability changes in the human small intestine

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 3, 2007, Pages 245-250

  Bours, Martijn J ^a,c   Troost, Freddy J ^a   Brummer, Robert Jan M ^b   Bast, Aalt ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ATP; Enteropathy; Indomethacin; Intestinal permeability; NSAID

Indexed keywords

ADENOSINE TRIPHOSPHATE; INDOMETACIN; LACTULOSE; PLACEBO; RHAMNOSE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRINKING; DRUG EFFECT; FEMALE; FLUORESCENCE ANALYSIS; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INGESTION; INTESTINE MUCOSA PERMEABILITY; INTUBATION; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SMALL INTESTINE; SMALL INTESTINE DISEASE; SMALL INTESTINE MUCOSA; STOMACH PAIN; URINALYSIS; URINARY EXCRETION;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOMETHACIN; INTESTINAL ABSORPTION; INTESTINE, SMALL; LACTULOSE; MALE; PERMEABILITY; RHAMNOSE;

EID: 33847064288     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328011093c     Document Type: Article

References (52)

1. Blower PR. Non-steroidal anti-inflammatory drugs. Br J Rheumatol 1993; 32 (Suppl 4):35-38.
2. Aabakken L. Small-bowel side-effects of non-steroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 1999; 11:383-388.
3. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832-1847.
4. Thiefin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72:286-294.
5. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of nonsteroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27:1292-1297.
6. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32:275-277.
7. Smecuol E, Bai JC, Sugai E, Vazquez H, Niveloni S, Pedreira S, et al. Acute gastrointestinal permeability responses to different non-steroidal antiinflammatory drugs. Gut 2001; 49:650-655.
8. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003; 18:479-497.
9. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002; 5:685-694.
10. Whittle BJ. Mechanisms underlying intestinal injury induced by antiinflammatory COX inhibitors. Eur J Pharmacol 2004; 500:427-439.
11. Agteresch HJ, Dagnelie PC, van den Berg JW, Wilson JH. Adenosine triphosphate: established and potential clinical applications. Drugs 1999; 58:211-232.
12. Schwiebert EM, Zsembery A. Extracellular ATP as a signaling molecule for epithelial cells. Biochim Biophys Acta 2003; 1615:7-32.
13. Roman RM, Fitz JG. Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Gastroenterology 1999; 116:964-979.
14. Leipziger J. Control of epithelial transport via luminal P2 receptors. Am J Physiol Renal Physiol 2003; 284:F419-F432.
15. Troost FJ, Saris WH, Brummer RJ. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003; 57:1579-1585.
16. Bjarnason I, Peters TJ,Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984; i:179-182.
17. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50:413-492.
18. Pals KL, Chang RT, Ryan AJ, Gisolfi CV. Effect of running intensity on intestinal permeability. J Appl Physiol 1997; 82:571-576.
19. van Nieuwenhoven MA, Geerling BJ, Deutz NE, Brouns F, Brummer RJ. The sensitivity of the lactulose/rhamnose gut permeability test. Eur J Clin Invest 1999; 29:160-165.
20. Meddings JB, Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology 1998; 114:83-92.
21. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34:407-411.
22. Bjarnason I, Smethurst P, Macpherson A,Walker F, McElnay JC, Passmore AP, et al. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992; 102:1546-1550.
23. Travis S, Menzies I. Intestinal permeability: functional assessment and significance [London]. Clin Sci 1992; 82:471-488.
24. Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30:289-299.
25. Ye J, Tsukamoto T, Sun A, Nigam SK. A role for intracellular calcium in tight junction reassembly after ATP depletion-repletion. Am J Physiol 1999; 277:F524-F532.
26. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, et al. Mitochondrial damage: a possible mechanism of the 'topical' phase of NSAID induced injury to the rat intestine. Gut 1997; 41:344-353.
27. Eliakim AR. Video capsule endoscopy of the small bowel (PillCam SB). Curr Opin Gastroenterol 2006; 22:124-127.
28. Davies NM. Review article: non-steroidal anti-inflammatory drug-induced gastrointestinal permeability. Aliment Pharmacol Ther 1998; 12:303-320.
29. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993; 104:1619-1626.
30. Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K. The G.U.T. of gut. Scand J Gastroenterol 2004; 39:807-815.
31. Grimble GK, Westwood OM. Nucleotides as immunomodulators in clinical nutrition. Curr Opin Clin Nutr Metab Care 2001; 4:57-64.
32. Sanchez-Pozo A, Gil A. Nucleotides as semiessential nutritional components. Br J Nutr 2002; 87 (Suppl 1):S135-S137.
33. McAlroy HL, Ahmed S, Day SM, Baines DL,Wong HY, Yip CY, et al. Multiple P2Y receptor subtypes in the apical membranes of polarized epithelial cells. Br J Pharmacol 2000; 131:1651-1658.
34. Coutinho-Silva R, Stahl L, Cheung KK, de Campos NE, de Oliveira Souza C, Ojcius DM, et al. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 2005; 288:G1024-G1035.
35. Gorodeski GI. Regulation of transcervical permeability by two distinct P2 purinergic receptor mechanisms. Am J Physiol Cell Physiol 2002; 282:C75-C83.
36. Gorodeski GI, Peterson DE, De Santis BJ, Hopfer U. Nucleotide receptor-mediated decrease of tight-junctional permeability in cultured human cervical epithelium. Am J Physiol 1996; 270:C1715-C1725.
37. Robaye B, Ghanem E, Wilkin F, Fokan D, Van Driessche W, Schurmans S, et al. Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y(4)-null mice. Mol Pharmacol 2003; 63:777-783.
38. Stutts MJ, Lazarowski ER, Paradiso AM, Boucher RC. Activation of CFTR Cl-conductance in polarized T84 cells by luminal extracellular ATP. Am J Physiol 1995; 268:C425-C433.
39. Dignass AU, Becker A, Spiegler S, Goebell H. Adenine nucleotides modulate epithelial wound healing in vitro. Eur J Clin Invest 1998; 28: 554-561.
40. Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001; 7:68-77.
41. Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease: immunology and repair mechanisms. Aliment Pharmacol Ther 2004; 20 (Suppl 4):9-17.
42. Swennen EL, Dagnelie PC, Bast A. ATP inhibits hydroxyl radical formation and the inflammatory response of stimulated whole blood even under circumstances of severe oxidative stress. Free Radic Res 2006; 40:53-58.
43. Swennen EL, Bast A, Dagnelie PC. Immunoregulatory effects of adenosine 5′-triphosphate on cytokine release from stimulated whole blood. Eur J Immunol 2005; 35:852-858.
44. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34:385-396.
45. Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion 2001; 63 (Suppl 1):93-96.
46. Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12:3789-3792.
47. Igarashi M, Takagi A, Jiang X, Hasumi K, Watanabe S, Deguchi R, et al. Analysis of Helicobacter pylori and nonsteroidal anti-inflammatory drug-induced gastric epithelial injury. Aliment Pharmacol Ther 2002; 16 (Suppl 2):235-239.
48. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84:282-291.
49. Meddings JB. Review article: intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 1997; 11 (Suppl 3):47-53; discussion 53-56.
50. Welcker K, Martin A, Kolle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004; 9:456-460.
51. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 1163-1169.
52. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999; 94:2956-2960.